|
Video: What is a Stock Split?
|
|
Amylyx Pharmaceuticals is a clinical stage biotechnology company. Co. is developing therapies for amyotrophic lateral sclerosis (ALS) and a range of other neurodegenerative diseases, including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, multiple sclerosis, Friedreich's ataxia, and Leigh's syndrome. Co. is pursuing commercialization of AMX0035, which is a drug candidate for patients with ALS. AMX0035 is a dual unfolded protein response-Bcl-2 Associated X-protein apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. According to our Amylyx Pharmaceuticals stock split history records, Amylyx Pharmaceuticals has had 0 splits. | |
|
Amylyx Pharmaceuticals (AMLX) has 0 splits in our Amylyx Pharmaceuticals stock split history database.
Looking at the Amylyx Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Amylyx Pharmaceuticals shares, starting with a $10,000 purchase of AMLX, presented on a split-history-adjusted basis factoring in the complete Amylyx Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/07/2022 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$18.07 |
|
End price/share: |
$1.88 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-89.60% |
|
Average Annual Total Return: |
-62.72% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,040.71 |
|
Years: |
2.29 |
|
|
|
|
|